High- Versus Low-Density PASCAL Laser Treatment for Proliferative Diabetic Retinopathy
CENTRAL MACULAR THICKNESS AFTER HIGH- VERSUS LOW-DENSITY SINGLE-SESSION PATTERN SCAN LASER PANRETINAL PHOTOCOAGULATION IN PROLIFERATIVE DIABETIC RETINOPATHY: A RANDOMIZED NON-INFERIORITY TRIAL
This study aims to compare the effects of high-density and low-density single-session Pattern Scan Laser (PASCAL) panretinal photocoagulation (PRP) in patients with proliferative diabetic retinopathy (PDR).
Panretinal photocoagulation is a standard treatment for proliferative diabetic retinopathy. However, the number of laser spots applied during a single treatment session varies in clinical practice. This study will investigate whether applying a higher number of laser spots in one session is as safe and effective as applying a lower number of spots, particularly regarding changes in central macular thickness.
Eligible patients with proliferative diabetic retinopathy who have not previously received PRP will be randomly assigned to one of two groups. The low-density group will receive 2,200-3,000 laser spots, while the high-density group will receive 3,200-4,000 laser spots using the PASCAL laser system in a single session.
Central macular thickness will be measured using optical coherence tomography (OCT) before treatment and four weeks after treatment. The main purpose is to determine whether high-density PRP is not inferior to low-density PRP in terms of changes in central macular thickness. Visual acuity and treatment-related adverse effects will also be assessed.
The findings may help determine whether a higher number of laser spots can be safely delivered in a single PASCAL PRP session without causing an unacceptable increase in macular thickness.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Ikke anvendelig
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
-
• Adults aged ≥ 18 years
- Type 1 or type 2 diabetes mellitus
- Treatment-naïve PDR with no clinically significant DME on OCT
- BCVA better than or equal to 6/60
- Baseline CMT <300 µm on Spectralis SD-OCT (central 1 mm ETDRS circle), with no intraretinal or subretinal fluid.
- Adequate pupil dilation and media clarity to perform OCT and laser photocoagulation
Exclusion Criteria:
- Other coexisting retinal eye diseases (ARMD, Retinal Vein Occlusion, Uveitis, tractional retinal detachments involving or threatening macula).
- Any previous retinal laser, anti-VEGF, or intravitreal/suprachoroidal steroid in the study eye.
- History of any intraocular surgery less than 6 months or Yag Capsulotomy less than 3 months in the study eye.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Dobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Aktiv komparator: Gruppe B
|
Participants will undergo single-session panretinal photocoagulation (PRP) using the PASCAL pattern scan laser system. A total of 2,200-3,000 laser spots will be applied to the peripheral retina. |
|
Aktiv komparator: Gruppe A
|
Participants will undergo single-session panretinal photocoagulation (PRP) using the PASCAL pattern scan laser system. A total of 3,200-4,000 laser spots will be applied to the peripheral retina |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Change in Central Macular Thickness
Tidsramme: 4 weeks
|
4 weeks
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- CHR-IREB-2026-0134
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .